

Scientific Program
Sunday, 9 September 2018

SY21	Symposium
9:00 – 10:30	Room A (3F Shinsho Hall)
Brain Development and Mental Disorder	
<i>Chairs: Norio Ozaki, Department of Psychiatry, Nagoya University Graduate School of Medicine, Japan Kazunori Nakajima, Department of Anatomy, Keio University School of Medicine, Japan</i>	

- SY21-1 Elucidation of molecular pathogenesis neurodevelopmental disorders, autistic spectrum disorder and schizophrenia starting from rare disease-susceptibility variants**
Norio Ozaki, Department of Psychiatry, Nagoya University Graduate School of Medicine, Japan
- SY21-2 Neurodevelopmental implications from neuroimaging and neurocognitive function studies on psychosis and psychosis high-risk states**
Jun Soo Kwon, Department of Psychiatry, Seoul National University, Republic of Korea
- SY21-3 Brain development in psychoses: Relevance of adult plasticity**
Peter Falkai, Department of Psychiatry, University of Munich, Germany
- SY21-4 Reelin function in the developing cerebral neocortex**
Kazunori Nakajima, Department of Anatomy, Keio University School of Medicine, Japan

PL-5	Plenary Lecture
10:30 – 11:15	Room A (3F Shinsho Hall)
Cellular, Circuit, and Behavioral Homeostasis in Treatment-Resistant Depression and Rapid-Acting Antidepressants	
<i>Chair: Tadafumi Kato, Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Japan</i>	

- PL-5 Cellular, Circuit, and Behavioral Homeostasis in Treatment-Resistant Depression and Rapid-Acting Antidepressants**
Carlos A. Zarate, Division Intramural Research Program, National Institute of Mental Health, USA

PL-6	Plenary Lecture
11:15 – 12:00	Room A (3F Shinsho Hall)
Recovery for Psychoses: A known concept with a potential for new treatment options	
<i>Chair: Masatoshi Takeda, Jinmeikai Research Institute for Mental Health, Japan</i>	

- PL-6 Recovery for Psychoses: A known concept with a potential for new treatment options**
Peter Falkai, Department of Psychiatry, University of Munich, Germany

LS-3

Luncheon Seminar

12:10 – 13:10

Room A (3F Shinsho Hall)

The Value provided by treatment with LAI : preventing relapse and working towards recovery

Chair: *Tadafumi Kato, Laboratory for Molecular Dynamics of Mental Disorders RIKEN Center for Brain Science Institute, Japan*

Co-sponsor: *Otsuka Pharmaceutical Co., Ltd.*

- LS-3 **The Value provided by treatment with LAI : preventing relapse and working towards recovery**
Nakao Iwata, Department of Psychiatry, Fujita Health University School of Medicine, Japan

SY24

Symposium

14:15 – 15:45

Room A (3F Shinsho Hall)

**What can we learn from brain imaging of schizophrenia research?
From its pathophysiology to actual treatment**

Chairs: *Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine, Japan*
Euitae Kim, Department of Psychiatry, Seoul National University College of Medicine, Republic of Korea

- SY24-1 **Can we predict relapse after antipsychotic discontinuation in first episode psychosis?**
Euitae Kim, Department of Psychiatry, Seoul National University College of Medicine, Republic of Korea
- SY24-2 **Glutamatergic dysfunction in treatment-resistant schizophrenia: a 3T proton MRS study**
Shinichiro Nakajima, Department of Neuropsychiatry, Keio University, Japan
- SY24-3 **Association of Hippocampal volume and dopamine transporter in medicated schizophrenia**
Yuan-Hwa Chou, Center for Quality Management and Department of Psychiatry, Taipei Veterans General Hospital, Taiwan
- SY24-4 **Brain imaging for guidance of psychotropic drug treatment**
Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine, Japan

SY22

Symposium

9:00 – 10:30

Room B (3F Conference Room 1)

Long-acting anti psychotics (LAIs) - The Australasian experience

Chairs: *Digvijay Singh Goel, Mental Health, Addictions & Intellectual Disability Directorate, Southland Hospital, New Zealand*

Mohan Isaac, Psychiatry, The University of Western Australia, Faculty of Health and Medical Sciences, Australia

- SY22-1 **Maintenance therapy in schizophrenia**
Mohan Isaac, Psychiatry, Faculty of Health and Medical Sciences, The University of Western Australia, Australia
- SY22-2 **Long Acting Antipsychotics: History and the progress**
Shailesh Kumar, Waikato Clinical Campus, University of Auckland, New Zealand
- SY22-3 **Is there an early role for LAIs (long-acting injectable antipsychotics)?**
Nagesh B Pai, Department of Psychiatry, Graduate Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Australia
- SY22-4 **Long-Acting Injectable Antipsychotics (LAIs): Looking ahead**
Digvijay Singh Goel, Mental Health, Addictions & Intellectual Disability Directorate, Southland Hospital, New Zealand

SY25	Symposium
14:15 – 15:45	Room B (3F Conference Room 1)
Cross-disorder biomarkers based on RDoC	
<i>Chairs: Norio Ozaki, Department of Psychiatry, Nagoya University Graduate School of Medicine, Japan Peter Falkai, Department of Psychiatry, University of Munich, Germany</i>	

- SY25-1 Genetic biomarkers based on RDoC**
Peter Falkai, Department of Psychiatry, University of Munich, Germany
- SY25-2 Molecule/Cell biomarkers based on RDoC; gut-brain-microbiome axis and behaviour**
Margaret J. Morris, Department of Pharmacology, UNSW Sydney, Australia
- SY25-3 Circuits/Physiology biomarkers based on RDoC**
Naohiro Okada, Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Japan
- SY25-4 Behavior/Self-Reports/Paradigms based on RDoC focusing on cognitive impairment**
Ryota Hashimoto, Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Japan

SS4	Scientific Session
9:00 – 10:20	Room C (3F Conference Room 2)
Schizophrenia/Psychopharmacology	
<i>Chairs: Alejo Corrales, Mental Health Department, Maimonides University, Medical Psychology, Psychiatry and Forensic Psychiatry Mental Health Department, National Argentinean University UNT, Argentina Kotaro Hatta, Department of Psychiatry, Juntendo University Nerima Hospital, Japan</i>	

- SS4-1 Comparison of the Outcomes of Patients with Severe Mental Illness by Legal Status: Community Treatment Orders vs. Voluntary Outpatient Treatment**
Nagesh B Pai, Department of Psychiatry, Graduate Medicine, University of Wollongong, Australia
- SS4-2 Efficacy of N-methyl-D-aspartate receptor enhancing agents on cognition in patients with schizophrenia**
Chun-Hung Chang, Psychiatric Department, China Medical University Hospital, Taiwan
- SS4-3 Structural changes in musical deficits in schizophrenia**
Ken Sawada, Department of Psychiatry, Kochi Health Science Center, Japan
- SS4-4 Response to antipsychotics and use of electroconvulsive therapy in acute-phase schizophrenia spectrum disorders**
Kotaro Hatta, Department of Psychiatry, Juntendo University Nerima Hospital, Japan
- SS4-5 Abnormal resting-state functional connectivity in schizophrenic patients with theory of mind deficit**
Dang Zheng, CAS Key Laboratory of Behavioral Science, Institute of Psychology, Chinese Academy of Sciences, China
- SS4-6 Comparison of the defined daily dose and chlorpromazine equivalent methods in antipsychotic drug utilization in six Asian countries**
Shih-Ku Lin, Psychiatry, Taipei City Hospital and Psychiatric Center, Taiwan
- SS4-7 Multiple versus single antipsychotic drug treatment of inpatients with schizophrenia in Asia**
Mian-Yoon Chong, Psychiatry, Chang Gung Memorial Hospital & Chang Gung University, Taiwan

Scientific Program

Sunday, 9 September 2018

- SS4-8** Widespread white matter microstructural abnormalities and their relationship with age in schizophrenia, bipolar disorder, and major depressive disorder: A tract-based spatial statistics study
Shinichi Yamada, Department of Neuropsychiatry, Wakayama Medical University, Japan

SS5

Scientific Session

14:15 – 15:45

Room C (3F Conference Room 2)

Depression/Sleep Disorders

*Chairs: Osamu Shirakawa, Department of Neuropsychiatry, Kindai University Faculty of Medicine, Japan
 Ulrich Sprick, Department of Dayclinics and Ambulances, St. Alexius/St. Josef Clinic, Neuss, Germany*

- SS5-1** Prediction of depressive state based on metabolome data of 897 subjects utilizing a non-linear machine learning model with feature selection
Yuta Takahashi, Tohoku Medical Megabank Organization, Tohoku University, Japan
- SS5-2** Wearable devices for evaluation of mood disorders: systematic review and meta-analysis
Yuuki Tazawa, Department of Psychiatry, Keio University School of Medicine, Japan
- SS5-3** Spot urine measurement of monoamines and steroid hormones as a precise method to distinguish medicated patients with depression from controls
Roger C Ho, Department of Psychological Medicine, National University of Singapore, Singapore
- SS5-4** Low cerebral oxy-haemoglobin as a biological marker of depressive symptoms
Syeda Fabeha Husain, Psychological Medicine, Naitonal University of Singapore, Singapore
- SS5-5** MiR-146a and miR-155, negative regulator microRNA for TLR4 signaling pathway, are biomarkers for major depressive disorder
Yi-Yung Hung, Department of Psychiatry, Kaohsiung Chang Gung Memorial hospital, Taiwan
- SS5-6** Neural exosomes from blood plasma as a biomarker of treatment-resistant major depressive disorder
Shoshin Akamine, Department of Mental Health Promotion, Osaka University, Japan
- SS5-7** Nonvisual effects of bright lamps designed to mimic natural outdoor light (HCL-Technique)
Ulrich Sprick, Department of Dayclinics and Ambulances, St. Alexius/St. Josef Clinic, Neuss, Germany
- SS5-8** The factors which affect percentage of slow wave sleep in obstructive sleep apnea syndrome
Masaki Koyama, Department of Mental Health Promotion, Osaka University Graduate School of Medicine, Japan
- SS5-9** Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients
Kuan-Pin Su, College of Medicine, China Medical University Taiwan, Taiwan

SY23

Symposium

9:00 – 10:30

Room D (3F Conference Room 3)

Dementia, biomarker and prevention

*Chairs: Masatoshi Takeda, Jinmeikai Research Institute for Mental Health, Japan
 Doh Kwan Kim, Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea*

- SY23-1** Heading toward Precision Medicine for Alzheimer's disease: Abeta modulator gene KLC1
Takashi Morihara, Department of Precision Medicine for Dementia, Osaka University, Japan

Scientific Program

Sunday, 9 September 2018

- SY23-2 Gender differences in risk factors for transition from MCI to AD based on cohort study from Korea**
Doh Kwan Kim, Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea
- SY23-3 Physical activity and body composition on cognitive function**
Misa Nakamura, Cognitive Reserve Research Center, Osaka Kawasaki Rehabilitation University, Japan
- SY23-4 Cognitive Training: a possible way of enhancing brain reserve and prevent dementia?**
Xin Yu, Clinical Research Division, Peking University Institute of Mental Health, China

SY26

Symposium

14:15 – 15:45

Room D (3F Conference Room 3)

Biomarkers for neurodevelopment and its disorders in animal and human

*Chairs: Hidenori Yamasue, Department of Psychiatry, Hamamatsu University School of Medicine, Japan
Kenji Tsuchiya, Center for Child Mental Development, Hamamatsu University School of Medicine, Japan*

- SY26-1 Constructing translatability in Autism Spectrum Disorder mouse models by quantifying behavior in a group**
Seico Benner, Department of Child Psychiatry, The University of Tokyo, Japan
- SY26-2 Perspective of Serological Biomarkers for Autism Spectrum Disorders (ASD)**
Shiro Suda, Department of Psychiatry, Jichi Medical University, Japan
- SY26-3 Atypical development of the central auditory system in young children with Autism spectrum disorder**
Mitsuru Kikuchi, Research Center for Child Mental Development, Kanazawa University, Japan
- SY26-4 Activated microglia in Attention-deficit/hyperactivity disorder: a positron emission tomography study**
Masamichi Yokokura, Department of Psychiatry, Hamamatsu University School of Medicine, Japan

MP2

Moderated Poster Session

13:15 – 14:15

Poster Room (2F Valencia)

Schizophrenia 1

Chair: Koichi Kaneko, Division of Neuropsychiatry, Department of Brain and Neuroscience, Tottori University Faculty of Medicine, Japan

- MP2-1 Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials**
Taro Kishi, Department of Psychiatry, Fujita Health University School of Medicine, Japan
- MP2-2 Safety and tolerability of Lurasidone versus Placebo in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies**
Katsuhiko Hagi, Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan
- MP2-3 Effect of Antipsychotics on Cognition in Patients with Schizophrenia : A Systematic Review and Meta-Analysis of Randomized Controlled Trials**
Katsuhiko Hagi, Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan
- MP2-4 Safety and Tolerability of Lurasidone in Asian patients with Schizophrenia: A Pooled Analysis of Phase III Randomized, Double-blind, Placebo-controlled Studies**
Katsuhiko Hagi, Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan

Scientific Program

Sunday, 9 September 2018

- MP2-5 Efficacy of Lurasidone versus Placebo in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies**
Tadashi Nosaka, Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan
- MP2-6 Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis**
Ikuo Nomura, Department of Psychiatry, Fujita Health University School of Medicine, Japan
- MP2-7 Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis**
Kenji Sakuma, Department of Psychiatry, Fujita Health University School of Medicine, Japan
- MP2-8 Longitudinal Change Of The State Of Metabolic Syndrome In Patients With Schizophrenia and Bipolar Disorder**
Nam Young Lee, Department of Psychiatry, Dongguk University Ilsan Hospital, Republic of Korea
- MP2-9 Metabolic Effects of Seven Antipsychotics on Patients with Schizophrenia during Early Stages of Treatment: a randomized, open-label, pharmacological trial**
Yamin Zhang, Mental Health Center and the Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, China

MP2

Moderated Poster Session

13:15 – 14:15

Poster Room (2F Valencia)

Schizophrenia 2

Chair: Yoshio Minabe, Department of Psychiatry and Behavioral Science, Kanazawa University Graduate School of Medical Sciences, Japan

- MP2-10 Candidate Biomarker in DNA Methylation of Serotonin Transporter Gene for Depression Treatment Outcome**
Lim Shinn-Won, SAIHST, Sungkyunkwan University School of Medicine, Republic of Korea
- MP2-11 The transdermal patch formulation of blonanserin (DSP-5423P) in the treatment of schizophrenia: a 6 week, randomized placebo-controlled study**
Nakao Iwata, Department of Psychiatry, Fujita Health University, Japan
- MP2-12 Long-term study of a transdermal patch formulation of blonanserin (DSP-5423P) in patients with schizophrenia**
Nakao Iwata, Department of Psychiatry, Fujita Health University, Japan
- MP2-13 The influence of plasma clozapine concentrations on heart rate variability in patients with schizophrenia: partial least square regression analysis**
Seong Hoon Jeong, Department of Psychiatry, Eulji University Hospital, Republic of Korea
- MP2-14 Clinical factors associated with the metabolic syndrome in patients with schizophrenia taking clozapine monotherapy**
Shi Hyun Kang, Department of General Psychiatry, National Center for Mental Health, Republic of Korea
- MP2-15 The Factors in Relation with Prolonged QTc Intervals in Chronic Schizophrenia Inpatients**
Jong-Ik Park, Department of Psychiatry, Kangwon National University, Republic of Korea
- MP2-16 Effects of Rivastigmine Patch on Cognitive Function and Body Weight: An Observational, Retrospective Study in Japanese Patients with Alzheimer Disease**
Yasuhiro Kaneda, Department of Psychiatry, Iwaki Clinic, Japan

Scientific Program
Sunday, 9 September 2018
MP2
Moderated Poster Session
13:15 – 14:15
Poster Room (2F Valencia)
Schizophrenia 3
Chair: Toshifumi Kishimoto, Department of Psychiatry, Nara Medical University, Japan

- MP2-17 Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine**
Manabu Takaki, Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
- MP2-18 Investigation of abnormal molecular pathways in LINE-1 regulation in the brain using embryonic poly(I:C) model mouse**
Yui Murata, Department of Molecular Brain Science, Kumamoto University, Japan
- MP2-19 Chronic blonanserin administration has neurotrophic, neurogenic, and anti-inflammatory properties in the brain of healthy male rats**
Yusuke Murata, Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan
- MP2-20 Effects of antipsychotics on prenatal immune stress-induced schizophrenia: studies on social behavior and GABAergic interneuron function changes**
Wataru Ukai, Department of Neuropsychiatry, Sapporo Medical University, Japan
- MP2-21 Metabolic Syndrome Caused by Antipsychotic Drugs and Haematological Changes**
Alejo Corrales, Neuroscience Department, Maimonides University, Argentina
- MP2-22 Effect of Saiko-ka-Ryukotsu-Borei-To on hyper-emotionality of olfactory bulbectomized rats**
Yuma Ogushi, Department of Psychiatry, Fukuoka University, Japan
- MP2-23 The ameliorating and preventive effects of blonanserin, an atypical antipsychotic drug, on phencyclidine induced cognitive deficits in rodents**
Masanori Miyachi, Research Division, Sumitomo Dainippon Pharma Co., Ltd., Japan
- MP2-24 Resequencing of the SETD1A gene in Japanese patients with schizophrenia**
Satoshi Hoya, Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Japan
- MP2-25 Rare FBXO18 variations and risk of schizophrenia**
Yuichiro Watanabe, Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Japan
- MP2-26 Whole-exome sequencing in a consanguineous multiplex family with schizophrenia and a case-control study**
Hirofumi Igeta, Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Japan

MP2
Moderated Poster Session
13:15 – 14:15
Poster Room (2F Valencia)
Schizophrenia 4
Chair: Toshiya Murai, Department of Psychiatry, Kyoto University Graduate School of Medicine, Japan

- MP2-27 Biochemical analysis of sphingolipid metabolism in postmortem brains from schizophrenia patients**
Kayoko Esaki, Center for Brain Science, RIKEN, Japan
- MP2-28 Increased serum levels and promoter polymorphisms of macrophage migration inhibitory factor in schizophrenia**
Satoshi Okazaki, Department of Psychiatry, Kobe University Graduate School of Medicine, Japan

Scientific Program

Sunday, 9 September 2018

- MP2-29 Mosaic loss of chromosome Y in peripheral blood and its risk variants in men with schizophrenia**
Takashi Hirata, Department of Psychiatry, Kobe University Graduate School of Medicine, Japan
- MP2-30 Altered plasma metabolites related to one-carbon metabolism in schizophrenia**
Yukiko Tomioka, Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Japan
- MP2-31 EEG Coherence Abnormalities in Patients with Schizophrenia and Their Unaffected Siblings**
Yu Sang Lee, Department of Psychiatry, Yongin Mental Hospital, Republic of Korea
- MP2-32 Association of therapeutic response and change of mismatch negativity in schizophrenia patients**
Won Sub Kang, Department of neuropsychiatry, College of Medicine, Kyung Hee University, Republic of Korea
- MP2-33 Clinical Characteristics of Formal Thought Disorder in Schizophrenia**
Hoseon Lee, Department of Psychiatry, Hanyang University Guri Hospital, Republic of Korea
- MP2-34 De Novo Mutations Revealed by Whole-exome Sequencing in Monozygotic Twins are Associated with Schizophrenia**
Lili Guan, Peking University Institute of Mental Health, China
- MP2-35 Altered striatal functional connectivity in patients with first episode psychosis**
Sang Hoon Oh, Department of Psychiatry, Seoul National University College of Medicine, Republic of Korea
- MP2-36 Aberrant fronto-temporal connectivity in first episode psychosis and its association with psychotic symptoms: a resting-state EEG study**
TaeUk Kang, Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea

MP2

Moderated Poster Session

13:15 – 14:15

Poster Room (2F Event Hall)

Bipolar Disorders and Depression 1

Chair: Masaya Yanagi, Department of Neuropsychiatry, Kindai University Faculty of Medicine, Japan

- MP2-37 Generation of mutant mice modeling de novo mutations found in bipolar disorder patients**
Takumi Nakamura, Department of Life Science, The University of Tokyo, Japan
- MP2-38 Effect of a de novo mutation of UNC13B found in a patient with bipolar disorder on the splicing pattern**
Kotori Jimbo, RIKEN Center for Brain Science, Laboratory for Molecular Dynamics of Mental Disorders, Japan
- MP2-39 Analysis of DNA methylation status of LINE-1 promoter region in postmortem brains of patients with bipolar disorder**
Hikari Matsubara, Department of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, Japan
- MP2-40 Mitochondrial DNA copy number of peripheral blood in bipolar disorder: the present study and a meta-analysis**
Naruhisa Yamaki, Department of Psychiatry, Kobe University Graduate School of Medicine, Japan
- MP2-41 Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment**
Shinichiro Ochi, Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Japan
- MP2-42 Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model**
Kai Zhang, Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Japan
- MP2-43 Antidepressant-like effect of blonanserin in a chronic mild stress model of depression**
Marco A. Riva, Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy

Scientific Program
Sunday, 9 September 2018

- MP2-44** **Effects of maternal separation on epigenetic regulation of the brain-derived neurotrophic factor exon I promoter in the rat hippocampus**
Younghoon Kim, Department of Psychiatry, Gongju National Hospital, Republic of Korea
- MP2-45** **Dissecting the critical region and neuronal activity for depression-related behavior in the rat mPFC**
Tatsuhiko Miyagi, Department of Psychiatry and Neurosciences, Hiroshima University, Japan
- MP2-46** **Lurasidone monotherapy in the treatment of bipolar I depression: A six-week multi-regional randomized, double-blind, placebo-controlled study**
Teruhiko Higuchi, Japan Depression Center, Japan

MP2
Moderated Poster Session
13:15 – 14:15
Poster Room (2F Event Hall)
Bipolar Disorders and Depression 2
Chair: Yasushi Ishida, Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Japan

- MP2-47** **Loss of chromosome Y in blood, but not in brain, of suicide completers**
Ikuo Otsuka, Department of Psychiatry, Kobe University Graduate School of Medicine, Japan
- MP2-48** **Suicide-related subcortical shape alterations in major depressive disorder**
Byung-Joo Ham, Department of Psychiatry, Korea University College of Medicine, Republic of Korea
- MP2-49** **The Association between Plasma Cholesterol and the Effect of Tryptophan Depletion on Heart Rate Variability**
Yen Kuang Yang, Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan
- MP2-50** **Psychotropic prescription patterns in patients with bipolar disorder in Taiwan**
Min-Shan Li, Department of Psychiatry, Taipei City Hospital Zhongxiao Branch, Taiwan
- MP2-51** **Preconditioning of lipopolysaccharide induces tolerance to depressive-like behavior**
Minori Koga, Department of Psychiatry, National Defense Medical College, Japan
- MP2-52** **PSYCHONEUROIMMUNOLOGY - 20 YEARS OF EXPERIENCE**
Olya A. Mikova, Psychiatry Unit, Foundation Biological Psychiatry, Bulgaria
- MP2-53** **Mood state and episode prediction of mood disorder by machine learning using automatic digital log data based on circadian rhythm**
Heon-Jeong Lee, Department of Psychiatry, Korea University College of Medicine, Republic of Korea
- MP2-54** **Efficacy and Safety/Tolerability of Atypical Antipsychotics in the Treatment of Bipolar Depression: A Systematic Review and Network Meta-analysis**
Katsuhiko Hagi, Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan
- MP2-55** **Candidate Genomic Markers for Depression Susceptibility**
Yoojin Jang, Dep. of Psychiatry, Samsung Medical Center, Republic of Korea

MP2
Moderated Poster Session
13:15 – 14:15
Poster Room (2F Event Hall)
Neuroimaging
Chair: Akira Iwanami, Department of Psychiatry, Showa University, Faculty of Medicine, Japan

- MP2-56** **The brain morphology of deficit and non-deficit schizophrenia: a voxel-based morphometric study**
Mikio Kido, Department of Neuropsychiatry, University of Toyama, Japan

- MP2-57 Altered activities in default mode network in patients with schizophrenia: using independent component analysis and dual regression method**
Woon Yoon, Department of Psychiatry, Asan Medical Center, Republic of Korea
- MP2-58 Altered connectivity between striatal and extrastriatal regions in schizophrenia: an [18F]fallypride PET and functional MRI study**
Jong-Hoon Kim, Department of Psychiatry, Gachon University School of Medicine, Gachon University, Republic of Korea
- MP2-59 The difference in brain activity of the prefrontal cortex between schizophrenia, bipolar disorder, and major depression**
Shinsuke Koike, University of Tokyo, Japan
- MP2-60 Lithium efficacy on the inferior frontal cortical activity in patients with bipolar disorder with a history of suicide attempts**
Tomoyuki Hirose, Department of Neuropsychiatry, Kindai University, Japan
- MP2-61 The correlation between work performance and front-temporal cerebral function in the depressive patients at work estimated by near-infrared spectroscopy**
Itsurou Ida, Department of Psychiatry, National Hospital Organization Takasaki General Medical Center, Japan
- MP2-62 Blood flow change in prefrontal cortex in Emotional stroop task using Near-Infrared Spectroscopy in mood disorders**
Yoshitaka Nishizawa, Psychiatry, Shin-awaji Hospital, Japan
- MP2-63 Measuring the resting-state activity of the medial prefrontal cortex in schizophrenia using near-infrared spectroscopy**
Fumiharu Hosomi, Department of Neuropsychiatry, Kindai University Faculty of Medicine, Japan
- MP2-64 Evaluation of Hemodynamic Changes with Near-Infrared Spectroscopy Among Patients with Tic-Related Obsessive Compulsive Disorder**
Keiichiro Mukai, Department of Neuropsychiatry, Hyogo College of Medicine, Japan